PL2953975T3 - Środek do immunoobrazowania do zastosowania w terapii skojarzonej przeciwciało-lek - Google Patents

Środek do immunoobrazowania do zastosowania w terapii skojarzonej przeciwciało-lek

Info

Publication number
PL2953975T3
PL2953975T3 PL14705455T PL14705455T PL2953975T3 PL 2953975 T3 PL2953975 T3 PL 2953975T3 PL 14705455 T PL14705455 T PL 14705455T PL 14705455 T PL14705455 T PL 14705455T PL 2953975 T3 PL2953975 T3 PL 2953975T3
Authority
PL
Poland
Prior art keywords
antibody
drug conjugate
imaging agent
conjugate therapy
immuno
Prior art date
Application number
PL14705455T
Other languages
English (en)
Inventor
Jochen Kruip
Sanjiv S. Gambhir
Susanta K. Sarkar
Mathias Gebauer
Christian Lange
Ingo Focken
Richard Kimura
Arutselvan Natarajan
Ohad Ilovich
Original Assignee
Sanofi
The Board Of Trustees Of The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi, The Board Of Trustees Of The Leland Stanford Junior University filed Critical Sanofi
Publication of PL2953975T3 publication Critical patent/PL2953975T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
PL14705455T 2013-02-05 2014-02-05 Środek do immunoobrazowania do zastosowania w terapii skojarzonej przeciwciało-lek PL2953975T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361761188P 2013-02-05 2013-02-05
EP14305081 2014-01-21
EP14705455.5A EP2953975B1 (en) 2013-02-05 2014-02-05 Immuno imaging agent for use with antibody-drug conjugate therapy
PCT/US2014/014903 WO2014124026A1 (en) 2013-02-05 2014-02-05 Immuno imaging agent for use with antibody-drug conjugate therapy

Publications (1)

Publication Number Publication Date
PL2953975T3 true PL2953975T3 (pl) 2018-02-28

Family

ID=50031281

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14705455T PL2953975T3 (pl) 2013-02-05 2014-02-05 Środek do immunoobrazowania do zastosowania w terapii skojarzonej przeciwciało-lek

Country Status (16)

Country Link
EP (1) EP2953975B1 (pl)
KR (1) KR20150113196A (pl)
CN (1) CN105143272A (pl)
AU (1) AU2014214997A1 (pl)
CA (1) CA2900255A1 (pl)
DK (1) DK2953975T3 (pl)
ES (1) ES2644668T3 (pl)
HU (1) HUE037456T2 (pl)
LT (1) LT2953975T (pl)
MX (1) MX2015010144A (pl)
PL (1) PL2953975T3 (pl)
PT (1) PT2953975T (pl)
RU (1) RU2015137856A (pl)
SG (1) SG11201506053VA (pl)
SI (1) SI2953975T1 (pl)
WO (1) WO2014124026A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117285631A (zh) * 2023-11-24 2023-12-26 原子高科股份有限公司 用于放射性免疫治疗的Lu-177标记MUC1抗体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001270609A1 (en) * 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
EP1917034A4 (en) * 2005-08-22 2009-04-29 Immunogen Inc CA6 ANTIGEN-SPECIFIC CYTOTOXIC CONJUGATE AND METHOD OF ITS APPLICATION
GB0822001D0 (en) * 2008-12-02 2009-01-07 Glaxosmithkline Biolog Sa Vaccine
KR20120060877A (ko) * 2009-09-01 2012-06-12 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
GB201005063D0 (en) * 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products

Also Published As

Publication number Publication date
HUE037456T2 (hu) 2018-08-28
PT2953975T (pt) 2017-10-30
DK2953975T3 (en) 2017-12-11
MX2015010144A (es) 2016-05-31
LT2953975T (lt) 2017-12-27
SG11201506053VA (en) 2015-08-28
EP2953975B1 (en) 2017-09-06
CN105143272A (zh) 2015-12-09
ES2644668T3 (es) 2017-11-29
AU2014214997A1 (en) 2015-08-20
EP2953975A1 (en) 2015-12-16
SI2953975T1 (en) 2018-02-28
KR20150113196A (ko) 2015-10-07
RU2015137856A (ru) 2017-03-13
CA2900255A1 (en) 2014-08-14
WO2014124026A1 (en) 2014-08-14

Similar Documents

Publication Publication Date Title
HUS2500038I1 (hu) Anti-trop2 antitest-gyógyszer konjugátum
IL287559A (en) Formulations of antibody-drug conjugate and cyclodextrin
IL274881A (en) Anti-EGFR antibody and drug conjugate formulations
SI3071237T1 (sl) Liofilizirana formulacija konjugata protitelo-zdravilo
IL246277A0 (en) Peptide-mimicking compounds and their antibody-drug conjugates
ZA201603697B (en) Peptidomimetic compounds and antibody-drug conjugates thereof
IL245437A0 (en) Antibodies against efna4 and antibody-drug pairs
SG10201707391QA (en) Immuno imaging agent for use with antibody-drug conjugate therapy
SG11201601628VA (en) Photoacoustic imaging contrast agent composition
SG11201506053VA (en) Immuno imaging agent for use with antibody-drug conjugate therapy
IL240371A0 (en) Immunogenic imaging agent for use with drug-antibody conjugate therapy
IL240370A0 (en) Immunogenic imaging agent for use with drug-antibody conjugate therapy
GB201310472D0 (en) Antibody-drug conjugates